No profile data available.
UroGen Pharma Ltd. (URGN) is a healthcare company in the additional cancer treatment drugs industry, based in Princeton, United States, with about 300 full-time employees.
It reported revenue of $109.79 million for fiscal year 2025, up 21.4% from fiscal year 2024, and net income of -$153.49 million. Its market capitalization was $1.80 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers.
UroGen Pharma reported $109.79 million in revenue for fiscal year 2025, up 21.4% from $90.40 million in fiscal year 2024.
$1.80 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Hutchmed (China) Limited (HCM), Immunome, Inc. (IMNM), Zymeworks Inc. (ZYME), Nuvation Bio Inc. (NUVB).